Medifast Reports Worsening Q1 2026 Results with 34% Revenue Drop and Expanded Net Loss
Summary
Medifast reported a 34.3% year-over-year revenue decline and a significantly expanded net loss for Q1 2026, driven by a sharp drop in active coaches and competitive pressures from GLP-1 medications.
Key Events
-
Revenue Plummets 34.3% Year-over-Year
Q1 2026 revenue decreased by $39.7 million to $76.0 million, compared to $115.7 million in Q1 2025, continuing a significant downward trend.
-
Net Loss Expands Significantly
The company reported a net loss of $2.1 million, a 174.9% increase from the $0.8 million net loss in Q1 2025.
-
Active Coach Network Shrinks Dramatically
The number of active earning coaches declined by 44.9% to 14,000 as of March 31, 2026, primarily due to the rapid adoption of GLP-1 medications.
-
Full Valuation Allowance on Deferred Tax Assets
Medifast maintained a full valuation allowance against its deferred tax assets, indicating management's uncertainty about generating sufficient future taxable income.
Analysis
Medifast's Q1 2026 results reveal a significant deterioration in financial performance, confirming and deepening concerns highlighted in the previous 10-K and an 8-K filed earlier today. Revenue plummeted by 34.3% year-over-year, driven by a substantial 44.9% decline in active earning coaches, which the company attributes to the rapid adoption of GLP-1 weight loss medications. This indicates that the competitive pressures are intensifying and the company's strategic transformation to metabolic health has not yet stemmed the decline. The net loss expanded by 174.9%, further impacting profitability. A critical negative signal is the continued full valuation allowance against deferred tax assets, suggesting management does not anticipate sufficient future taxable income to utilize these assets. While the company maintains a stable total asset base, cash and cash equivalents decreased by $17.8 million in the quarter, and net cash from operating activities was minimal, raising questions about cash runway if losses persist. The detailed financial statements in this 10-Q provide crucial context to the headline numbers previously released.
At the time of this filing, MED was trading at $11.00 on NYSE in the Manufacturing sector, with a market capitalization of approximately $117.3M. The 52-week trading range was $9.22 to $15.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.